Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 4 recruiting now early-phase tilt small index

ASD: early-phase trial registry

4 of 8 indexed ASD trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #2,176 of 28,707 conditions by registered trial count.

8 US clinical trials · 4 currently recruiting · #2,176 of 28,707 conditions by registered trial count

ASD: 8 US clinical trials tracked, 4 recruiting.

ASD is the subject of 8 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is Joanne Kurtzberg, MD, running 1 of these trials.

Enrollment posture brief

Registry condition asd

OPEN 4 | RECR 50% | LATE 0 | EARLY 4 | RANK #2176 | SPON 1

Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)

Activity, Motor75%Achalasia50%ASD (this)50%Abdominal Cancer25%Acne Scars - Mixed Atrophic 25%
Open-enrollment share among volume-matched conditions near ASD

ASD lists 4 open slots (50% of 8 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for ASD on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. ASD is recruiting above its size-band peers.

    4 of 8 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of ASD trials is spread across many organizations.

    Joanne Kurtzberg, MD accounts for 1 of 8 trials (12.5%). 8 distinct sponsors appear on at least one study for this condition label.

  3. Typical ASD enrolment sits around 100 participants.

    Median target enrolment is 100 among the 8 trials that report a genuine target (sentinel values excluded). 4 of those (50%) plan for fewer than 100 participants.

  4. ASD research is mostly interventional.

    7 interventional and 1 observational studies make up this index (87.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 11Phase 23

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 3

Named interventions

Most-linked intervention names on ASD records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

98% pure CBD Drug
1 trials
Cord Blood Infusion Biological
1 trials
Intranasal Oxytocin Drug
1 trials
Transcranial Magnetic Stimulation Sham Procedure
1 trials
MM402 (R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA)) Drug
1 trials
Transcranial Magnetic Stimulation Procedure
1 trials
Home-Based Pivotal Response Treatment (PRT Intervention (PRT-H) Behavioral
1 trials
Center-Based Pivotal Response Treatment (PRT) Intervention (PRT-C) Behavioral
1 trials

US sites by state

Facility locations filed on ASD trials. A trial with sites in several states counts in each.

Ohio 2 trials
New York 2 trials
Massachusetts 2 trials
California 2 trials
North Carolina 1 trials
Florida 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this ASD page

8 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This ASD condition card totals 8 registered trials; most-linked intervention 98% pure CBD; top US site state Ohio. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.